- Home
- Publications
- Publication Search
- Publication Details
Title
Is Targeted Therapy Feasible in Acute Myelogenous Leukemia?
Authors
Keywords
Acute myelogenous leukemia, Pathogenesis, Chemotherapeutic strategies, Relapse, Molecular markers
Journal
Current Hematologic Malignancy Reports
Volume 9, Issue 2, Pages 118-127
Publisher
Springer Nature
Online
2014-03-05
DOI
10.1007/s11899-014-0198-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents
- (2013) C. Dos Santos et al. BLOOD
- FLT3 inhibitor-induced neutrophilic dermatosis
- (2013) A. T. Fathi et al. BLOOD
- Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia
- (2013) O. Abdel-Wahab et al. BLOOD
- Genomic impact of transient low-dose decitabine treatment on primary AML cells
- (2013) J. M. Klco et al. BLOOD
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
- (2013) F. Ravandi et al. BLOOD
- Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study
- (2013) Anjali Shah et al. BRITISH JOURNAL OF HAEMATOLOGY
- Hematopoietic Stem Cell Mobilization for Gene Therapy: Superior Mobilization by the Combination of Granulocyte–Colony Stimulating Factor Plus Plerixafor in Patients with β-Thalassemia Major
- (2013) Evangelia Yannaki et al. HUMAN GENE THERAPY
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia
- (2012) A. F. T. Ribeiro et al. BLOOD
- A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
- (2012) G. L. Uy et al. BLOOD
- Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML
- (2012) A. Sexauer et al. BLOOD
- A novel hierarchical prognostic model of AML solely based on molecular mutations
- (2012) V. Grossmann et al. BLOOD
- Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia
- (2012) P. Yan et al. BLOOD
- The Origin and Evolution of Mutations in Acute Myeloid Leukemia
- (2012) John S. Welch et al. CELL
- BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies
- (2012) M. R. Kuhne et al. CLINICAL CANCER RESEARCH
- Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
- (2012) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
- (2012) R M Stone et al. LEUKEMIA
- 5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity
- (2012) N Curik et al. LEUKEMIA
- High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
- (2012) S K Metzelder et al. LEUKEMIA
- The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison
- (2012) A K Burnett et al. LEUKEMIA
- ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome
- (2012) S Schnittger et al. LEUKEMIA
- A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
- (2012) Laurens Kruidenier et al. NATURE
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
- (2012) Jay P. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML)
- (2011) Friederike Schneider et al. ANNALS OF HEMATOLOGY
- ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
- (2011) K. H. Metzeler et al. BLOOD
- TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics
- (2011) W.-C. Chou et al. BLOOD
- Clinical Implications of Novel Mutations in Epigenetic Modifiers in AML
- (2011) Omar Abdel-Wahab et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
- (2011) P. Lund et al. MOLECULAR CANCER THERAPEUTICS
- Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value
- (2010) S. Abbas et al. BLOOD
- DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights
- (2010) Rainer Claus et al. Future Oncology
- Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
- (2010) G. Borthakur et al. HAEMATOLOGICA
- IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
- (2010) F. Thol et al. HAEMATOLOGICA
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
- (2010) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
- (2010) Peter Paschka et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
- (2010) Thomas Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
- (2010) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative Analysis of Small Molecules and Histone Substrate Analogues as LSD1 Lysine Demethylase Inhibitors
- (2010) Jeffrey C. Culhane et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
- (2009) O. Abdel-Wahab et al. BLOOD
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells
- (2009) C Flotho et al. LEUKEMIA
- High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
- (2009) Bob Löwenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway
- (2009) Kwong-Kwok Wong Recent Patents on Anti-Cancer Drug Discovery
- Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century
- (2008) D. Pulte et al. HAEMATOLOGICA
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
- (2008) Alex A. Adjei et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
- (2008) Weiguo Zhang et al. JNCI-Journal of the National Cancer Institute
- Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
- (2008) J A McCubrey et al. LEUKEMIA
- Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
- (2008) L S Steelman et al. LEUKEMIA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now